Cardiac involvement remains a significant and potentially fatal manifestation of sarcoidosis. The diagnosis and management of CS remain challenging due to its diverse presentations and the limitations of biopsy. Current international guidelines emphasize a multimodal diagnostic approach, where advanced imaging techniques, such as cardiac MRI with LGE and PET, play a crucial role in diagnosis, disease monitoring, and risk stratification.

The integration of PET with MRI represents a significant advancement, maintaining MRI's diagnostic sensitivity while incorporating PET's ability to detect inflammation. This combination offers valuable insights into both the inflammatory and fibrotic phases of the disease. Ultimately, this integrated approach enhances our understanding and management of CS.